[go: up one dir, main page]

WO1999047131A3 - Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase - Google Patents

Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase Download PDF

Info

Publication number
WO1999047131A3
WO1999047131A3 PCT/GB1999/000778 GB9900778W WO9947131A3 WO 1999047131 A3 WO1999047131 A3 WO 1999047131A3 GB 9900778 W GB9900778 W GB 9900778W WO 9947131 A3 WO9947131 A3 WO 9947131A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
inverse agonist
gaba
alpha
acetylcholinesterase inhibitor
Prior art date
Application number
PCT/GB1999/000778
Other languages
English (en)
Other versions
WO1999047131A2 (fr
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme
Gerard Raphael Dawson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Gerard Raphael Dawson filed Critical Merck Sharp & Dohme
Priority to JP2000536371A priority Critical patent/JP2002506815A/ja
Priority to AU28464/99A priority patent/AU753077B2/en
Priority to CA002323618A priority patent/CA2323618A1/fr
Priority to EP99909095A priority patent/EP1061952A2/fr
Publication of WO1999047131A2 publication Critical patent/WO1999047131A2/fr
Publication of WO1999047131A3 publication Critical patent/WO1999047131A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur une combinaison d'un inhibiteur d'acétylcholinestérase et d'un agoniste inverse du sous-type du récepteur α5 GABAA, sur l'utilisation de cette combinaison dans le traitement de maladies neurodégénératives comme la maladie d'Alzheimer.
PCT/GB1999/000778 1998-03-16 1999-03-16 Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase WO1999047131A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000536371A JP2002506815A (ja) 1998-03-16 1999-03-16 ＧＡＢＡＡα５逆作動薬とアセチルコリンエステラーゼ阻害剤との組合わせ
AU28464/99A AU753077B2 (en) 1998-03-16 1999-03-16 Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
CA002323618A CA2323618A1 (fr) 1998-03-16 1999-03-16 Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase
EP99909095A EP1061952A2 (fr) 1998-03-16 1999-03-16 Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
GB9805561.9 1998-03-16

Publications (2)

Publication Number Publication Date
WO1999047131A2 WO1999047131A2 (fr) 1999-09-23
WO1999047131A3 true WO1999047131A3 (fr) 1999-11-04

Family

ID=10828631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000778 WO1999047131A2 (fr) 1998-03-16 1999-03-16 Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase

Country Status (6)

Country Link
EP (1) EP1061952A2 (fr)
JP (1) JP2002506815A (fr)
AU (1) AU753077B2 (fr)
CA (1) CA2323618A1 (fr)
GB (1) GB9805561D0 (fr)
WO (1) WO1999047131A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
WO2001092257A1 (fr) 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides et leur utilisation comme ligands des recepteurs cerebraux gaba
WO2002000623A2 (fr) 2000-06-26 2002-01-03 Neurogen Corporation 4-oxy-pyridines substituees a fusion aryle
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
CA2511599A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20050267077A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (fr) 2006-11-30 2012-04-18 Probiodrug AG Nouveaux inhibiteurs de glutaminylcyclase
EP2481408A3 (fr) 2007-03-01 2013-01-09 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
MX2017014774A (es) 2015-05-22 2018-02-15 Agenebio Inc Composiciones farmaceuticas de levetiracetam de liberacion extendida.
KR101743960B1 (ko) * 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
WO1996025948A1 (fr) * 1995-02-23 1996-08-29 Merck Sharp & Dohme Limited PREPARATION ET UTILISATION D'UN LIGAND SPECIFIQUE DU RECEPTEUR GABA-Aα5 DESTINE AU TRAITEMENT DE LA MALADIE D'ALZHEIMER
WO1998004560A1 (fr) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited DERIVES DE TRIAZOLO-PYRIDAZINE SUBSTITUES UTILISES COMME AGONISTES INVERSES DU SOUS-TYPE DE RECEPTEUR GABAAα5

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
WO1996025948A1 (fr) * 1995-02-23 1996-08-29 Merck Sharp & Dohme Limited PREPARATION ET UTILISATION D'UN LIGAND SPECIFIQUE DU RECEPTEUR GABA-Aα5 DESTINE AU TRAITEMENT DE LA MALADIE D'ALZHEIMER
WO1998004560A1 (fr) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited DERIVES DE TRIAZOLO-PYRIDAZINE SUBSTITUES UTILISES COMME AGONISTES INVERSES DU SOUS-TYPE DE RECEPTEUR GABAAα5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSENBERG D R ET AL: "COGNITIVE ENHANCING AGENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, vol. 26, no. 7, 1 October 1990 (1990-10-01), pages 449 - 471, XP000616601, ISSN: 0025-7656 *

Also Published As

Publication number Publication date
GB9805561D0 (en) 1998-05-13
CA2323618A1 (fr) 1999-09-23
JP2002506815A (ja) 2002-03-05
WO1999047131A2 (fr) 1999-09-23
AU753077B2 (en) 2002-10-10
EP1061952A2 (fr) 2000-12-27
AU2846499A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
WO1999047131A3 (fr) Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase
AU2001293936A1 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
HK1033907A1 (en) Metal chelators for use in the treatment of alzheimer's disease.
AU2002366641A1 (en) Methods for inhibiting ocular processes
ATE279407T1 (de) Fsh mimetika zur behandlung von infertilität
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
JP2000503980A5 (fr)
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
EP1201268A3 (fr) Compositions pharmaceutiques contenant des antagonistes du récepteur D4 de dopamine et des inhibiteurs de l' Acetylcholinesterase
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
CA2418167A1 (fr) Compositions et procedes permettant de prevenir ou de reduire le risque ou la frequence des blessures du squelette chez les chevaux
HUT74948A (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
HK1046002B (zh) 免疫調節性類固醇，特別是16α-溴表雄酮的半水合物
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
NO992504L (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
GB9805559D0 (en) A combination of therapeutic agents
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
WO1999051779A3 (fr) Traitement et diagnostic du glaucome
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
NO20005386D0 (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999909095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09622954

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 28464/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2323618

Country of ref document: CA

Ref country code: CA

Ref document number: 2323618

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999909095

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 28464/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999909095

Country of ref document: EP